Leukocyte extract reduces HIV replication and modulates cellular factors involved in HIV infection: therapeutic meant by Fernandez-Ortega, C et al.
POSTER PRESENTATION Open Access
Leukocyte extract reduces HIV replication and
modulates cellular factors involved in HIV
infection: therapeutic meant
C Fernandez-Ortega
1*, D Casillas
1, M Dubed
2, L Navea
2, A Ramirez
3, L Lopez
3, T Paneque
3, Y Reinoso
3
From Tenth International Congress on Drug Therapy in HIV Infection
Glasgow, UK. 7-11 November 2010
Background
The development of antiretroviral therapies to combat
human immunodeficiency virus (HIV) infection has
resulted in a decrease in morbidity and mortality asso-
ciated with the acquired immunodeficiency syndrome
(AIDS). Despite these therapeutic advances, problems of
drug resistance, latent viral reservoirs, and drug induced
toxic effects that compromise effective viral control
point to the need for new classes of anti-HIV drugs
with different modes of action. Dialyzable Leukocyte
Extract (DLE) is a low molecular weight dialyzable
material obtained from human leukocytes. A clinical
trial of six years of follow-up was carried out using a
DLE preparation in asymptomatic HIV patients.
Twenty-eight percent of the untreated individual
showed disease progression, while only progressed to
AIDS 7% of DLE-treated patients. These results indicate
that DLE delays disease progression. However, the mole-
cular basis supporting this effect remained unknown.
Purpose of the study
To demonstrate anti-HIV activity in DLE and show DLE
modulation on cellular factors involved in HIV replication.
Methods
Using an in vitro infection model on MT4 cell line we
study the effect of DLE on HIV replication. We study
the effect of DLE on important cellular factors like
NFkB, Sp1 and TNF in MT4 cells or peripheral blood
mononuclear cells.
Summary of results
DLE shows a significant inhibitory effect on HIV repli-
cation ranged from 80-90% according to the viral chal-
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Figure 1 2.5×105 cell/mL were treated for 24 or 72 hours with 0.15 or 0.3 U/mL DLE. Leukocyte extract was removed and cells were infected
with HIV-Bru isolate at moi 0.05 or 0.1 for 1 hour. Fresh medium containing DLE was added after virus challenge. p24 antigen was measured
seven days after infection. Errors bars indicate SD, n=9.
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modulation of important endogenous factors involved in
HIV immunopathogenesis like TNFa (figure 2) and tran-
scription factors NFB and Sp1.
Conclusions
DLE effect on cellular factors involved in HIV replica-
tion correlates with DLE inhibitory effect on HIV in
vitro replication. The inhibition of HIV replication
observed with DLE treatment could be mediated by
inhibition of transcription factors that may promote
replication of HIV. Also, it could be mediated or poten-
tiated by modulation TNF and others endogenous fac-
tors involved in HIV replication. These finding could
support the use of DLE on HIV patients.
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Figure 2 Whole blood was treated with LPS (4 ng/mL) and DLE. TNF was measured using ELISA. Results are representative of six experiments
using blood from different donors. Errors bars indicate SD.
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